Bacterial and Fungal Co-infections Among COVID-19 Patients in Intensive Care Unit
Overview
Microbiology
Affiliations
This study aimed to investigate the frequency and characteristics of respiratory co-infections in COVID-19 patients in the intensive care unit (ICU). In this retrospective observational study, pathogens responsible for potential co-infections were detected by the bacterial culture, real-time polymerase chain reaction (RT-PCR), or serological fungal antigen tests. Demographic and clinical characteristics, as well as microbial results, were analyzed. Bacterial culture identified 56 (58.3%) positive samples for respiratory pathogens, with the most common bacteria being Burkholderia cepacia (18, 18.8%). RT-PCR detected 38 (76.0%) and 58 (87.9%) positive results in the severe and critical groups, respectively. Most common pathogens detected were Stenotrophomonas maltophilia (28.0%) and Pseudomonas aeruginosa (28.0%) in the severe group and S. maltophilia (45.5%) in the critical group. P. aeruginosa was detected more during the early stage after ICU admission. Acinetobacter baumannii and Staphylococcus aureus were more frequently identified during late ICU admission. Fungal serum antigens were more frequently positive in the critical group than in the severe group, and the positive rate of fungal serum antigens frequency increased with prolonged ICU stay. A high frequency of respiratory co-infections presented in ICU COVID-19 patients. Careful examinations and necessary tests should be performed to exclude these co-infections.
Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children.
Hoshino W, da Silva A, Pignatari A, Gales A, Carlesse F Braz J Infect Dis. 2025; 29(2):104515.
PMID: 39985933 PMC: 11893299. DOI: 10.1016/j.bjid.2025.104515.
Pintea-Simon I, Bancu L, Mare A, Ciurea C, Toma F, Brukner M J Clin Med. 2024; 13(20).
PMID: 39458151 PMC: 11508343. DOI: 10.3390/jcm13206201.
Mortality in hospitalized SARS-CoV-2 patients with contemporaneous bacterial and fungal infections.
Hanna J, Most Z, Cooper L, Wakene A, Radunsky A, Lehmann C Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e142.
PMID: 39346658 PMC: 11428019. DOI: 10.1017/ash.2024.424.
Strateva T, Stratev A, Peykov S Pathogens. 2024; 13(9).
PMID: 39338911 PMC: 11435151. DOI: 10.3390/pathogens13090719.
Co-Infection of SARS-CoV-2 and : A Systematic Review and Meta-Analysis.
Chagas A, Araujo J, Serra J, Araujo K, Cunha M, Correia A Diagnostics (Basel). 2024; 14(11).
PMID: 38893674 PMC: 11171625. DOI: 10.3390/diagnostics14111149.